These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35461090)

  • 1. Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma.
    Thumrongsiri N; Dana P; Bawab R; Tanyapanyachon P; Treetidnipa C; Saengkrit N; Sathornsumetee S
    Biomed Pharmacother; 2022 Jun; 150():112979. PubMed ID: 35461090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
    Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
    Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
    Li L; Yang J; Wang J; Kopeček J
    ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
    Miyake Y; Okoshi Y; Machino T; Chiba S
    Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
    Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
    Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
    Beum PV; Kennedy AD; Taylor RP
    J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma.
    Song L; Chen Y; Ding J; Wu H; Zhang W; Ma M; Zang F; Wang Z; Gu N; Zhang Y
    J Mater Chem B; 2020 Feb; 8(5):895-907. PubMed ID: 31909406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression.
    Song L; Zhang W; Chen H; Zhang X; Wu H; Ma M; Wang Z; Gu N; Zhang Y
    Int J Nanomedicine; 2019; 14():921-936. PubMed ID: 30787607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma.
    Wang T; Kievit FM; Veiseh O; Arami H; Stephen ZR; Fang C; Liu Y; Ellenbogen RG; Zhang M
    World Neurosurg; 2013; 80(1-2):134-41. PubMed ID: 23298674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
    Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
    J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system.
    Jin J; Joo KM; Nam Y; Kim DH; Lee SJ; Jo MY; Jin Y; Kim HS; Seo SW; Kim SJ; Nam DH; Kim WS
    Exp Ther Med; 2010 Nov; 1(6):943-946. PubMed ID: 22993623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
    Pels H; Schulz H; Schlegel U; Engert A
    Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
    Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
    Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
    Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
    J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.